IN2015DN00528A - - Google Patents

Info

Publication number
IN2015DN00528A
IN2015DN00528A IN528DEN2015A IN2015DN00528A IN 2015DN00528 A IN2015DN00528 A IN 2015DN00528A IN 528DEN2015 A IN528DEN2015 A IN 528DEN2015A IN 2015DN00528 A IN2015DN00528 A IN 2015DN00528A
Authority
IN
India
Prior art keywords
combination
proliferative disease
subject
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
Other languages
English (en)
Inventor
Giordano Caponigro
Xizhong Huang
Joseph Lehar
hui qin Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2015DN00528A publication Critical patent/IN2015DN00528A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN528DEN2015 2012-08-16 2013-08-14 IN2015DN00528A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261683790P 2012-08-16 2012-08-16
PCT/US2013/054848 WO2014028566A1 (fr) 2012-08-16 2013-08-14 Combinaison d'un inhibiteur pi3k et d'un inhibiteur c-met

Publications (1)

Publication Number Publication Date
IN2015DN00528A true IN2015DN00528A (fr) 2015-06-26

Family

ID=49004065

Family Applications (1)

Application Number Title Priority Date Filing Date
IN528DEN2015 IN2015DN00528A (fr) 2012-08-16 2013-08-14

Country Status (14)

Country Link
US (5) US20150216870A1 (fr)
EP (1) EP2885003B1 (fr)
JP (3) JP2015529194A (fr)
KR (2) KR102245985B1 (fr)
CN (1) CN105050623B (fr)
AU (4) AU2013302702A1 (fr)
BR (1) BR112015002528A2 (fr)
CA (1) CA2879704A1 (fr)
ES (1) ES2901712T3 (fr)
HK (1) HK1211476A1 (fr)
IN (1) IN2015DN00528A (fr)
MX (1) MX369518B (fr)
RU (1) RU2705095C2 (fr)
WO (1) WO2014028566A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140069235A (ko) 2011-09-27 2014-06-09 노파르티스 아게 돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
JP2015512425A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
US9296733B2 (en) 2012-11-12 2016-03-29 Novartis Ag Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
EP2970240B1 (fr) 2013-03-14 2018-01-10 Novartis AG 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante
KR20160020502A (ko) * 2013-06-18 2016-02-23 노파르티스 아게 제약 조합물
CA2917858A1 (fr) 2013-08-02 2015-02-05 Aduro Biotech Holdings, Europe B.V. Combinaison d'agonistes cd27 et d'inhibiteurs de points de controle immunitaires pour une stimulation immune
US10085993B2 (en) 2014-07-25 2018-10-02 Novartis Ag Tablet formulation of 2-fluoro-N-methyl-4-[ 7-( quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide
US10689459B2 (en) 2014-12-12 2020-06-23 Novartis Ag Treatment of breast cancer brain metastases
GB201516504D0 (en) 2015-09-17 2015-11-04 Astrazeneca Ab Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
AU2020404995A1 (en) * 2019-12-20 2022-07-14 Recurium Ip Holdings, Llc Combinations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0211649D0 (en) * 2002-05-21 2002-07-03 Novartis Ag Organic compounds
GB0510390D0 (en) * 2005-05-20 2005-06-29 Novartis Ag Organic compounds
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
ME02372B (me) * 2006-11-22 2016-06-20 Incyte Holdings Corp Imidazotriazini i imidazopiramidini kao inhibitori kinaze
US9370508B2 (en) * 2007-02-20 2016-06-21 Novartis Ag Imidazoquinolines as dual lipid kinase and mTOR inhibitors
MX2010009743A (es) * 2008-03-05 2010-09-28 Novartis Ag Uso de derivados de pirimidina para el tratamiento de las enfermedades dependientes de los receptores del factor de crecimiento epidermico (egfr) o de enfermedades que hayan adquirido resistencia a los agentes que se dirigen a los miembros de la fami
WO2009143211A2 (fr) * 2008-05-21 2009-11-26 Incyte Corporation Sels de 2-fluoro-n-méthyl-4-[7-(quinoléin-6-yl-méthyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide et procédés associés à leur préparation
KR20110028651A (ko) * 2008-07-11 2011-03-21 노파르티스 아게 (ａ) 포스포이노시타이드 3-키나제 억제제 및 (ｂ) ｒａｓ/ｒａｆ/ｍｅｋ 경로의 조절제의 조합물
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US20100267742A1 (en) * 2009-04-17 2010-10-21 Rush University Medical Center Combination targeted therapy for lung cancer
AR083267A1 (es) * 2010-10-04 2013-02-13 Novartis Ag Combinaciones farmaceuticas
CA2815492C (fr) * 2010-11-08 2019-04-09 Novartis Ag Utilisation de derives 2-carboxamide cycloamino uree dans le traitement de maladies dependantes d'egfr ou de maladies qui ont acquis une resistance aux agents qui ciblent des memb res de la famille d'egfr

Also Published As

Publication number Publication date
ES2901712T3 (es) 2022-03-23
KR20150043328A (ko) 2015-04-22
AU2019226212B2 (en) 2020-05-14
AU2019226212A1 (en) 2019-09-26
US20190350935A1 (en) 2019-11-21
AU2016238903A1 (en) 2016-10-27
US20190083500A1 (en) 2019-03-21
KR102245985B1 (ko) 2021-04-30
RU2015108755A (ru) 2016-10-10
MX2015002005A (es) 2015-10-08
JP6644042B2 (ja) 2020-02-12
JP2015529194A (ja) 2015-10-05
US20200253980A1 (en) 2020-08-13
JP6970217B2 (ja) 2021-11-24
JP2018035188A (ja) 2018-03-08
KR20210049187A (ko) 2021-05-04
AU2013302702A1 (en) 2015-02-19
CN105050623B (zh) 2018-06-12
BR112015002528A2 (pt) 2018-05-22
RU2705095C2 (ru) 2019-11-05
EP2885003A1 (fr) 2015-06-24
WO2014028566A1 (fr) 2014-02-20
AU2018201725A1 (en) 2018-04-05
HK1211476A1 (en) 2016-05-27
MX369518B (es) 2019-11-11
CA2879704A1 (fr) 2014-02-20
JP2020079243A (ja) 2020-05-28
US20220280523A1 (en) 2022-09-08
EP2885003B1 (fr) 2021-09-29
CN105050623A (zh) 2015-11-11
US20150216870A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
IN2015DN00528A (fr)
ZA201800022B (en) Substituted heterocyclyl derivatives as cdk inhibitors
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
MX2016008362A (es) Combinaciones farmaceuticas.
NZ703940A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
MY178634A (en) Topical formulation for a jak inhibitor
IN2015DN00376A (fr)
MX371119B (es) Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
PH12016502353A1 (en) Pharmaceutical composition
WO2015095834A3 (fr) Traitements du cancer faisant appel à des inhibiteurs des familles erk1/2 et bcl-2
MX2016002580A (es) Combinacion de un inhibidor de alk y un inhibidor de cdk para el tratamiento de enfermedades celulares proliferativas.
UA107550C2 (uk) Похідні естра-1,3,5(10),16-тетраєн-3-карбоксаміду, способи їх одержання, фармацевтичні препарати, що їх містять, та їх застосування для виготовлення лікарських засобів
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
TW201613577A (en) Pharmaceutical combinations
WO2016109217A3 (fr) Inhibiteurs de la btk
PH12020500096A1 (en) Therapeutic combination of a third generation egfr tyrosine kinase inhibitor and a raf inhibitor
WO2018027084A3 (fr) Combinaison d'antagonistes de récepteur du glucagon et d'inhibiteurs de la voie pi3k pour le traitement du cancer
HK1254635A1 (zh) C-met抑制剂与pd-1抗体分子的组合及其用途
AU2018256668A1 (en) Combination therapy comprising an inhibitor of JAK, CDK and PIM
BR112015012497A2 (pt) combinações farmacêuticas
NZ602807A (en) 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor
EA201792314A1 (ru) Фармацевтическая комбинация эверолимуса и дактолисиба